Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication
暂无分享,去创建一个
L. Townsend | J. Drach | G. Koszalka | K. Biron | S. Good | S. Chamberlain | L. Boyd | N. W. Johnson
[1] R. Harvey,et al. Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l-Riboside with a Unique Mode of Action , 2002, Antimicrobial Agents and Chemotherapy.
[2] S. Chou. Antiviral drug resistance in human cytomegalovirus , 1999, Transplant infectious disease : an official journal of the Transplantation Society.
[3] L. Frick,et al. Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. , 1999, Advances in experimental medicine and biology.
[4] D. Jabs,et al. Incidence of Foscarnet Resistance and Cidofovir Resistance in Patients Treated for Cytomegalovirus Retinitis , 1998, Antimicrobial Agents and Chemotherapy.
[5] D. Jabs,et al. Cytomegalovirus Retinitis and Viral Resistance: Ganciclovir Resistance , 1998 .
[6] P. Wutzler,et al. Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. , 1996, Antiviral research.
[7] C. Crumpacker,et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. , 1995, The New England journal of medicine.
[8] S. Spector,et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. , 1995, The Journal of infectious diseases.
[9] J. C. Martin,et al. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. , 1995, The Journal of infectious diseases.
[10] W. Owen,et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. , 1994, The Journal of infectious diseases.
[11] R R Tice,et al. In vivo rodent erythrocyte micronucleus assay. , 1994, Mutation research.
[12] R. Schiestl,et al. Evaluation of the yeast DEL assay with 10 compounds selected by the International Program on Chemical Safety for the evaluation of short-term tests for carcinogens. , 1994, Mutation research.
[13] S. Clissold,et al. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. , 1991, Drugs.
[14] D. Faulds,et al. Ganciclovir , 2012, Drugs.
[15] C. Leport,et al. [Treatment of Cytomegalovirus infection]. , 1990, La Revue du praticien.
[16] D. Kirkland,et al. Statistical evaluation of mutagenicity test data , 1989 .
[17] H. Deeg,et al. Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogs , 1988, Antimicrobial Agents and Chemotherapy.
[18] Williams Da,et al. A note on Shirley's nonparametric test for comparing several dose levels with a zero-dose control , 1986 .
[19] A. Badr. Cytogenetic activities of a triazine herbicide in root tips of Allium cepa and Vicia faba , 1983 .
[20] B. Ames,et al. Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.
[21] D. Clive,et al. Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells. , 1975, Mutation research.
[22] B. Ames,et al. An improved bacterial test system for the detection and classification of mutagens and carcinogens. , 1973, Proceedings of the National Academy of Sciences of the United States of America.